Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [210]

Summary of breaking prostate news from ASCO 2014

Prof Eleni Efstathiou and Prof Gordon McVie

Summary of breaking prostate news from ASCO 2014 ( Prof Eleni Efstathiou and Prof Gordon McVie )

Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014

Prof Franco Cavalli, Prof Gordon McVie

Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014 ( Prof Franco Cavalli, Prof Gordon McVie )

Idelalisib shows promising results in patients with double refractory indolent...

Dr Andrew Davies - Southampton General Hospital, Southampton, UK;

$Idelalisib shows promising results in patients with double refractory indolent B-cell non-Hodgkin's lymphoma ( Dr Andrew Davies - Southampton General Hospital, Southampton, UK; )$

New agents extend progression-free survival in double refractory myeloma

Dr Jonathan Kaufman - Winship Cancer Institute of Emory University, Atlanta...

$New agents extend progression-free survival in double refractory myeloma ( Dr Jonathan Kaufman - Winship Cancer Institute of Emory University, Atlanta, USA )$

Role of AORTIC in dealing with rising cancer rates in Africa

North American Vice president of AORTIC

Role of AORTIC in dealing with rising cancer rates in Africa ( North American Vice president of AORTIC )

ALSYMPCA trial: Ra-223 effective and well-tolerated for CRPC with symptomatic...

Dr Sten Nilsson - Karolinska University Hospital, Stockholm, Sweden

ALSYMPCA trial: Ra-223 effective and well-tolerated for CRPC with symptomatic bone metastases ( Dr Sten Nilsson - Karolinska University Hospital, Stockholm, Sweden )

More from ecancer